Genentech’s Siegel: Why Not More Accelerated Approvals In Immunology?
Podcast – A former FDA official now at Genentech, Jeffrey Siegel talks about unmet need in rheumatology and potential opportunities with the agency for speeding things up outside of oncology.
You may also be interested in...
Keeping Track: Chugai Delivers Two Breakthroughs For Roche; FDA Continues To Wrestle With Opioid Regulation
The latest drug development news and highlights from our FDA Performance Tracker.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.